Inverse correlation between p16INK4A expression and NF-κB activation in melanoma progression

Human Pathology

Volumn 35, Issue 8, 2004, Pages 1029-1037

  Ghiorzo, Paola ^a,f   Mantelli, Michela ^a   Gargiulo, Sara ^a   Gramigni, Claudia ^b   Pastorino, Lorenza ^a   Banelli, Barbara ^c   Villaggio, Barbara ^d   Coccia, Maria Cristina ^c   Sementa, Angela Rita ^e   Garrè, Cecilia ^a   Bianchi Scarrà, Giovanna ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e G GASLINI INSTITUTE   (Italy)

^f V Le Benedetto XV 6 16132 ^*  (Italy)

Author keywords

CDK; CDKN2A p16INK4A; cyclin dependent kinase; electrophoretic mobility shift assay; EMSA; expression; immunohistochemistry; LOH; loss of heterozygosity; melanoma progression; NF; NF B p65; NHEM; normal human epithelial melanocytes; nuclear factor; TNF

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P16; SYNAPTOTAGMIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTASIS; NEVUS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR BIOPSY;

CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; MELANOMA; NEVUS; NF-KAPPA B; SKIN NEOPLASMS;

EID: 3843099360     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.02.017     Document Type: Article

References (31)

1. Serrano M., Hannon G.J., Beach D., et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707
2. Rocco J.W., Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 264:2001;42-55
3. Reed J.A., Loganzo F.J., Shea C.R., et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor-suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 55:1995;2713-2718
4. Talve L., Sauroja I., Collan Y., et al. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 74:1997;255-259
5. Keller-Melchior R., Schmidt R., Piepkorn M. Expression of the tumor-suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol. 110:1998;932-938
6. Straume O., Sviland L., Akslen L.A. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 6:2000;1845-1853
7. Pavey S.J., Cummings M.C., Whiteman D.C., et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res. 12:2002;539-547
8. Fung D.C., Holland E.A., Becker T.M., et al. eMelanoBase an online locus-specific variant database for familial melanoma. Hum Mutat. 21:2003;2-7
9. Ghiorzo P., Villaggio B., Sementa A.R., et al. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. HUM PATHOL. 35:2004;25-33
10. Walker G.J., Gabrielli B.G., Castellano M., et al. Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer. 82:1999;305-312
11. ARF. J Biol Chem. 276:2001;41424-41434
12. Becker T.M., Rizos H., Kefford R.F., et al. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding. Clin Cancer Res. 7:2001;3282-3288
13. Wolff B., Naumann M. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-κB. Oncogene. 18:1999;2663-2666
14. Mercurio F., Manning A.M. Multiple signals converging on NF-κB. Curr Opin Cell Biol. 11:2000;226-232
15. Perkins N.D. The Rel/NF-κB family Friend and foe. Trends Biochem Sci. 25:2000;434-440
16. Tam W.F., Lee L.H., Davis L. Cytoplasmic sequestration of rel proteins by IκB-α requires CRM1-dependent nuclear export. Mol Cell Biol. 20:2000;2269-2284
17. Luque I., Gelinas C. Rel/NF-κB and IκB factors in oncogenesis. Semin Cancer Biol. 8:1997;103-111
18. Gilmore T.D., Koedood M., Piffat K.A., et al. Rel/NF-κB/IκB proteins and cancer. Oncogene. 13:1996;1367-1378
19. Dhawan P., Singh A.B., Ellis D.L., et al. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res. 62:2002;7335-7342
20. Chen F., Castranova V., Shi X. New insights into the role of nuclear factor-κB in cell growth regulation. Am J Pathol. 159:2001;387-397
21. Hinz M., Krappmann D., Eichten A. NF-κB function in growth control Regulation of cyclin D1 expression and G0/G1- to S-phase transition. Mol Cell Biol. 19:1999;2690-2698
22. Guttridge D.C., Albanese C., Reuther J.Y. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 19:1999;5785-5799
23. Han D., Pottin-Clemenceau C., Imro M., et al. IL-2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL-2/INFα biotherapy. Oncogene. 12:1996;1015-1023
24. Barzegar C., Meazza R., Pereno R., et al. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene. 16:1998;2503-2512
25. INK4A) gene in 62 Italian malignant melanoma families. Am J Med Genet. 107:2002;214-221
26. Herman J.G., Graff J.R., Myohanen S., et al. Methylation-specific PCR A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 93:1996;9821-9826
27. Andrews N.C., Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:1991;2499
28. Shattuck-Brandt R., Richmond A. Enhanced degradation of I-κB alpha contributes to endogenous activation of NF-κB in Hs294T melanoma cells. Cancer Res. 57:1997;3032-3039
29. Kumar R., Sauroja R., Punnonen K., et al. Selective deletion of exon 1B of the p19 ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer. 23:1998;273-277
30. Graves P.R., Yu L., Schwarz J.K. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem. 275:2000;5600-5605
31. Hutchins J.R., Hughes M., Clarke P.R. Substrate specificity determinants of the checkpoint protein kinase Chk1. FEBS Lett. 466:2000;91-95